Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386500 | 0.86 | POLB (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL8474798 | 0.85 | POLB (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL9211270 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL9684628 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL2389473 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL9685672 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL2389980 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL9380136 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL9865528 | 0.84 | MCOLN3 (0.50) | POLBALDH1A1KMT2ALMNAMCOLN3 | |
| SCHEMBL13309094 | 0.84 | POLB (0.48) | POLBALDH1A1KMT2ALMNAMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | POLB 2243/4885ALDH1A1 882/4885KMT2A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.